Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 8.8% – Here’s Why

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s stock price shot up 8.8% during mid-day trading on Friday . The stock traded as high as $10.38 and last traded at $10.52. 145,699 shares changed hands during trading, a decline of 17% from the average session volume of 174,689 shares. The stock had previously closed at $9.67.

Theravance Biopharma Stock Up 8.3 %

The stock has a 50 day moving average of $9.47 and a 200 day moving average of $8.92.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The firm had revenue of $16.87 million during the quarter, compared to analyst estimates of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. During the same quarter in the prior year, the business earned ($0.17) earnings per share. Analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new stake in shares of Theravance Biopharma during the third quarter valued at approximately $60,000. China Universal Asset Management Co. Ltd. lifted its position in Theravance Biopharma by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 3,696 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in Theravance Biopharma during the 2nd quarter valued at $108,000. Ballentine Partners LLC purchased a new stake in Theravance Biopharma during the 3rd quarter valued at $104,000. Finally, XTX Topco Ltd purchased a new position in shares of Theravance Biopharma in the second quarter worth $129,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.